|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Chimeric antigen receptor-modified (CAR-modified) T cells have shown promising therapeutic effects for hematological malignancies, yet limited and inconsistent efficacy against solid tumors.
|
29769444 |
2018 |
|
Solid Neoplasm
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
High-Throughput Flow Cytometric Method for the Simultaneous Measurement of CAR-T Cell Characterization and Cytotoxicity against Solid Tumor Cell Lines.
|
29634393 |
2018 |
|
Solid Neoplasm
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Here, we reviewed the solid tumor CAR-T clinical trials, emphasizing the studies with published results.
|
29433552 |
2018 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Application of the CAR targeting strategy in solid tumors is challenged by the need for adequate target antigens.
|
30483473 |
2018 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Infiltration, accumulation, and survival of chimeric antigen receptor T (CAR-T) cells in solid tumors is crucial for tumor clearance.
|
29505028 |
2018 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The obstacles that reduce the efficacy of CAR-T therapy in solid tumors include a lack of specific tumor antigens, limited trafficking and penetration of CAR-T cells to tumor sites, and an immunosuppressive tumor microenvironment.
|
29861325 |
2018 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These adjuvant-like effects of GSK3 inhibition on activated CAR-T cells may be a valuable adjunct to a successful implementation of CAR-T immunotherapy against GBM and other solid tumors.
|
29959057 |
2018 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Identifying targets for chimeric antigen receptor-modulated T lymphocyte (CAR-T) therapy against solid tumors is an urgent problem to solve.
|
29935762 |
2018 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
New regimens, including combinations with chemical drugs, need to be studied to enhance the therapeutic efficacy of CAR-T or NK cells for solid tumors.
|
30410941 |
2018 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Clinical success of CAR-T cell monotherapy in solid tumors however, has been only modest.
|
30298067 |
2018 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We, herein, comment on the most salient aspects of CAR-T cell design and clinical experience in the treatment of solid tumors.
|
29203440 |
2018 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In this review, we discuss the structure of the CAR, current clinical advantages from finished and ongoing trials, adverse effects, challenges and controversies, new engineering methods of CAR, and clinical considerations that are associated with CAR T cell therapy both in hematological malignancies and solid tumors.
|
30108584 |
2018 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
CAR T-cell Therapy for Solid Tumors?
|
30291124 |
2018 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
However, the performance of CAR-T cell treatment in solid tumor is not as satisfactory as that in hematologic disease.
|
29769134 |
2018 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
CAR design optimization for solid tumors is crucial due to the absence of truly restricted antigen expression and potential safety concerns with "on-target off-tumor" activity.
|
29061641 |
2018 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Whereas much of the early success with CAR-T cells has been demonstrated with hematological malignancies, important barriers remain for the application of CAR-T cell therapies for the management of metastatic solid tumors.
|
27910858 |
2017 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Overall, our data document the superiority of local production of PD-L1 mini-body by CAd-VEC<i>PDL1</i> combined with administration of tumor-directed CAR T cells to control the growth of solid tumors.<i></i>.
|
28235763 |
2017 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Two preclinical studies indicate the potential of using biodegradable nanoparticles to program circulating T cells into CAR T cells <i>in situ</i>, and delivering these therapeutic cells directly to solid tumors via small dissolvable sponges.
|
28500027 |
2017 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Chimeric antigen receptor T (CAR-T) cells have shown promising efficacy in treatment of hematological malignancies, but its applications in solid tumors need further exploration.
|
28366766 |
2017 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
CAR-T cell therapy has achieved gratifying breakthrough in hematological malignancies and promising outcome in solid tumor as showed in various clinical trials.
|
28356156 |
2017 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Combining CAR-T or CAR-NK cells with chemotherapeutic drugs to treat solid tumor may be a promising strategy.
|
29423418 |
2017 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Thus, these devices may improve the effectiveness of CAR T cell therapy in solid tumors and help protect against the emergence of escape variants.
|
28436934 |
2017 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Specifically, this review covered the following areas: (1) the current status of CAR-T cells in the treatment of solid tumors; (2) the major factors constraining the efficacy of CAR-T cells in solid tumors; and (3) opinions regarding the future of CAR-T as a treatment for solid tumors.
|
29048935 |
2017 |
|
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
In addition, we will discuss extrinsic factors that can be manipulated to influence CAR-T performance such as choice of cellular population, culturing conditions and additional modifications that enhance their activity particularly in solid tumors.
|
26797495 |
2016 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
This strategy may facilitate the application of immunotherapy to solid tumors by affording comparable efficacy with improved safety owing to switch-based control of the CAR-T response.
|
27145250 |
2016 |